HAE Earnings Prediction
The chart below shows how HAE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HAE sees a +3.65% change in stock price 10 days leading up to the earnings, and a -1.70% change 10 days following the report. On the earnings day itself, the stock moves by -1.15%. This data can give you a slight idea of what to expect for the next quarter's release.
HAE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
336.25M
10.14%
5.68%
Gross Margin
52.94%
7.34%
3.12%
Operating Margin
19.34%
21.87%
4.09%
Net Margin
9.29%
-13.90%
18.65%
EPS
0.61
-4.69%
27.08%
No Data Available
HAE Earnings Analysis
Haemonetics Corp Corporation (HAE.N) Earnings Conference Call
Positive
Q3 Revenue and Earnings Growth: Third quarter revenue reached $349 million, reflecting a 4% growth on a reported basis and a 14% increase in adjusted earnings per share to $1.19, indicating strong financial performance.
Hospital Revenue Surge: Hospital revenue grew 24% in the third quarter and 28% year to date, with organic growth of 12-14%, showcasing robust demand in this segment.
Revenue Increase and Market Growth: Blood Management Technologies saw a 10% revenue increase in the quarter, driven by sustained market growth and share gains, contributing positively to overall performance.
Gross Margin Improvement: Adjusted gross margin improved to 57.7%, a 240 basis point increase year-over-year, driven by favorable volume growth and an improved portfolio mix.
Operating Income Performance: Adjusted operating income for the third quarter was $89.4 million, a 25.7% margin, reflecting a 150 basis point sequential expansion and a 390 basis point increase year-over-year, indicating effective cost management and operational efficiency.
Negative
Plasma Revenue Decline: Revenue from plasma declined 9% in the quarter and 5% year to date, with North America disposables revenue down 11% in the quarter and 6% year to date, indicating a significant setback in this segment.
Blood Center Revenue Decline: Blood center revenue declined 3% in the third quarter and 2% year to date, primarily due to the whole blood portfolio rationalization, reflecting challenges in maintaining revenue levels post-divestiture.
Rising Operating Expenses: Adjusted operating expenses year to date increased by $23.9 million or 8% compared to the prior year, indicating rising costs that could pressure profitability despite revenue growth.
Organic Plasma Revenue Decline: The company updated its organic plasma revenue guidance to a 5% to 7% decline, inclusive of approximately $100 million from CSL U.S. disposables, highlighting ongoing challenges in this area.
Revenue Guidance Revision: Despite a record third quarter margin, the overall revenue guidance was revised to a decline of 7% to 9% for reported revenue, indicating a negative outlook for the upcoming quarter.
HAE FAQs
How does HAE typically perform around its earnings report dates?
Is Haemonetics Corp (HAE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HAE Earning Call Sentiment
Earnings call transcript: Haemonetics Q3 2024 sees EPS beat, stock drops
HAE.N
1.44%Positive
Despite strong financial performance, including record operating income and increased EPS, the outlook is tempered by challenges such as difficult market conditions in China, increased competition, and operational hurdles in new product launches. The reaffirmed and raised guidance for certain segments provides some optimism, but concerns over supply chain issues and the impact of the whole blood business divestiture balance the positives. The Q&A section revealed a cautious tone from analysts, with management providing optimistic yet vague responses. The market cap suggests a moderate reaction, leading to a neutral stock price prediction.
